CADLCandel Therapeutics Inc. Common Stock
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Ph…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Candel Therapeutics (CADL) Faces Bigger Losses As Its Valuation Still Looks Pricey Candel Therapeutics (CADL) drew attention after reporting second quarter 2026 results that showed a net loss of US$38.91 million, compared with US$4.8 million a year earlier, indicating increased operating pressures. See our latest analysis for Candel Therapeutics. The latest earnings release landed alongside sharp share price gains for Candel Therapeutics, with a 1-day share price return of 12.03% and a 90-day share price return of 70.24%. The 3-year total shareholder return is also very... | ||
 CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4 If the FDA approves aglatimagene besadenovec in the treatment of certain patients with prostate cancer, it would mark the company’s first commercial product. | ||
 CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug — Eyes $10–$16B Opportunity Shares of Candel have drawn rising attention as the company advances its experimental immunotherapy, known as CAN-2409 or aglatimagene, toward potential approval in localized prostate cancer. | ||
 Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up Candel Therapeutics (NASDAQ:CADL) is advancing two off-the-shelf viral immunotherapy candidates designed for local administration intended to generate systemic immune responses against tumors, Chief Scientific Officer Francesca Barone said at the Canaccord Genuity Growth Conference in Boston. The c | ||
EExec Edge | ||